Back/Piedmont Oncology Enhances Pancreatic Cancer Detection with Major Philanthropic Donation
cancer·March 12, 2026·pdm

Piedmont Oncology Enhances Pancreatic Cancer Detection with Major Philanthropic Donation

ED
Editorial
Cashu Markets·2 min read
TL;DR
  • Piedmont Oncology's donation establishes the Sherron Berg Early Detection Pancreatic Cancer Program to improve detection and treatment.
  • The EDC at Piedmont Atlanta Hospital is Georgia's first clinic focused on early pancreatic cancer detection and resources.
  • Dr. Andrew Page emphasizes the need for ongoing philanthropic support to enhance patient outcomes and research initiatives.

Piedmont Oncology Strengthens Commitment to Pancreatic Cancer Detection with Major Philanthropic Donation

Piedmont Oncology elevates its commitment to combating pancreatic cancer through a substantial philanthropic donation aimed at enhancing its Early Detection Pancreatic Cancer Clinic (EDC) and establishing an endowed medical director position. This investment transforms the clinic into the Sherron Berg Early Detection Pancreatic Cancer Program, named in honor of Sherron Berg, a patient who recently underwent surgery for Stage 2 pancreatic cancer. The generous donation not only strengthens clinical operations but also spearheads vital research initiatives that could pave the way for groundbreaking advances in detection and treatment.

The EDC, which opened in November 2025 at Piedmont Atlanta Hospital, stands out as Georgia’s first specialized facility dedicated to early pancreatic cancer detection. It offers comprehensive risk assessments, promotes awareness, and enhances patient and clinician access to crucial resources. Dr. Andrew Page, the clinic’s founder and the newly appointed Sherron Berg Endowed Medical Director, expresses excitement about the potential of this philanthropic gift to transform the clinic’s capabilities. He emphasizes the essential nature of ongoing philanthropic support as they work towards improving outcomes for patients with this aggressive form of cancer, which has a notably low five-year survival rate of just 13%.

With this rebranding and the establishment of a dedicated clinical space recognized as the Sherron Berg Surgical Oncology and Hepato-Pancreato Biliary Surgery Clinic, Piedmont Oncology not only enhances its mission but also aligns itself with the vision of the Berg family. Their focus on early detection and innovative treatments reflects an urgent need in the community, given the increasing prevalence and impact of pancreatic cancer. This initiative, supported through donations via a dedicated website, highlights the critical role of philanthropy in advancing healthcare and emphasizes the collaborative nature of efforts aimed at tackling cancer, one of the leading causes of mortality in the United States.

In addition to expanding clinical offerings, the EDC boosts research partnerships that can lead to improved treatment protocols and outcomes for patients. By enhancing awareness and facilitating better access to necessary medical resources, Piedmont Oncology is poised to make a significant impact in the fight against pancreatic cancer. Those interested in supporting this transformative initiative can contribute through the designated channels, ensuring that advancements in early detection continue to progress in saving lives.

Cashu Markets
Cashu
Markets

By Cashu Markets. Providing market news, analysis, and research for investors worldwide.

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Markets is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Markets is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Markets and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Markets
Cashu
Markets

Setting up your session...